All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

21

Reset

21 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • siRNAADX-038, ADX-324Phase 37 trials

    ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1

  • CemdisiranALN-CC5Phase 35 trials

    Regeneron · Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD)

  • TinlarebantLBS-008Phase 33 trials

    Belite Bio, Inc · Stargardt Disease 1, STGD1, Geographic Atrophy

  • JNJ-81201887AAVCAGsCD59Phase 32 trials

    Johnson & Johnson (Janssen) · Geographic Atrophy, Macular Degeneration

  • VonaprumentANX007Phase 32 trials

    Annexon, Inc. · Geographic Atrophy

  • BS01Phase 22 trials

    Bionic Sight LLC · Retinitis Pigmentosa, Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

  • OpRegenPhase 22 trials

    Roche (Genentech) · Age-Related Macular Degeneration, Geographic Atrophy

  • STL303Phase 22 trials

    Sitala Bio LTD · IgAN, Geographic Atrophy

  • ABBV-6628Phase 21 trial

    AbbVie · Geographic Atrophy, Age-Related Macular Degeneration

  • APL-3007Phase 21 trial

    Apellis Pharmaceuticals, Inc. · Geographic Atrophy Secondary to Age-related Macular Degeneration

  • AVD-104Phase 21 trial

    Aviceda Therapeutics, Inc. · Geographic Atrophy of the Macula, Macular Degeneration

  • BI 1584862Phase 21 trial

    Boehringer Ingelheim · Geographic Atrophy

  • BI 771716Phase 21 trial

    Boehringer Ingelheim · Macular Degeneration, Age-related, Geographic Atrophy

  • BRX011Phase 21 trial

    Biojiva LLC · Geographic Atrophy

  • FWY003Phase 21 trial

    Novartis · Geographic Atrophy Secondary to Age-related Macular Degeneration

  • GAL-101Phase 21 trial

    Galimedix Therapeutics Inc · Geographic Atrophy of the Macula

  • PST-611Phase 21 trial

    Eyevensys · Geographic Atrophy, Age - Related Macular Degeneration (AMD)

  • RO7965032Phase 21 trial

    Roche (Genentech) · Geographic Atrophy Secondary to Age-Related Macular Degeneration

  • SAR446597Phase 21 trial

    Sanofi · Geographic Atrophy

  • SOM-401Phase 21 trial

    Inflammasome Therapeutics · Geographic Atrophy, Age-Related Macular Degeneration

  • VOY-101Phase 21 trial

    Perceive Biotherapeutics, Inc. · Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.